Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6261483 | 0.94 | NFKB1 (0.48) | ALDH1A1NFKB1GPR84FFAR4FFAR1 | |
| SCHEMBL11624224 | 0.92 | GPR84 (0.50) | ALDH1A1NFKB1GPR84FFAR4FFAR1 | |
| SCHEMBL11692164 | 0.92 | GPR84 (0.50) | ALDH1A1NFKB1GPR84FFAR4FFAR1 | |
| SCHEMBL6382813 | 0.92 | GPR84 (0.50) | ALDH1A1NFKB1GPR84FFAR4FFAR1 | |
| SCHEMBL10906089 | 0.92 | GPR84 (0.50) | ALDH1A1NFKB1GPR84FFAR4FFAR1 | |
| SCHEMBL11689543 | 0.92 | GPR84 (0.50) | ALDH1A1NFKB1GPR84FFAR4FFAR1 | |
| SCHEMBL11692251 | 0.92 | GPR84 (0.50) | ALDH1A1NFKB1GPR84FFAR4FFAR1 | |
| SCHEMBL6294221 | 0.92 | GPR84 (0.50) | ALDH1A1NFKB1GPR84FFAR4FFAR1 | |
| SCHEMBL10947381 | 0.92 | GPR84 (0.50) | ALDH1A1NFKB1GPR84FFAR4FFAR1 | |
| Pentanal SCHEMBL9053313 | 0.88 | TSHR (0.47) | ALDH1A1NFKB1GPR84FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706747-B2 | TREATING ELEVATED INTRAOCULAR PRESSURE, DEPRESSION, NON INSULIN-DEPENDENT DIABETES, MALE IMPOTENCE AND OBESITY WHICH IS ALLEVIATED BY TREATMENT WITH AN ALPHA 2 BLOCKING AGENT | ALLERGAN, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030187047-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ALLERGAN SALES, INC. | 2003-10-02 | — | — | US | disclosed |
| US-6569884-B2 | Trans-2-(3-phenyl-bicyclo(2.2.1)heptyl)-2-aminooxazoline, for example; treating intraocular pressure, noninsulin-dependent diabetes, male impotence and obesity | ALLERGAN | 2003-05-27 | — | — | US | disclosed |
| US-20020049241-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ALLERGAN SALES, INC. | 2002-04-25 | — | — | US | disclosed |
| EP-0770068-B1 | CONFORMATIONALLY RIGID BICYCLIC AND ADAMANTANE DERIVATIVES USEFUL AS ALPHA 2-ADRENERGIC BLOCKING AGENTS | ALLERGAN SALES INC (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6319935-B1 | USED IN TREATMENT OF ELEVATED INTRAOCULAR PRESSURE, NON INSULIN-DEPENDENT DIABETES, MALE IMPOTENCE AND OBESITY | ALLERGAN SALES, INC. | 2001-11-20 | — | — | US | disclosed |
| US-6150389-A | ANTIDEPRESSANTS; TREATING ELEVATED INTRAOCULAR PRESSURE, E.G., GLAUCOMA; ANTIDIABETIC AGENTS FOR NON-INSULIN DEPENDENT DIABETES, SEXUAL DISORDERS, E.G., MALE IMPOTENCE AND OBESITY; E.G. TRANS-2-(3-PHENYL-BICYCLO(2.2.1)HEPTYL)-2-AMINOOXAZOLINE | ALLERGAN SALES, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-5731337-A | Conformationally rigid bicycle and adamantane derivatives useful as α2 | ALLERGAN (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0770068-A1 | CONFORMATIONALLY RIGID BICYCLIC AND ADAMANTANE DERIVATIVES USEFUL AS ALPHA 2-ADRENERGIC BLOCKING AGENTS | Allergan (US) | 1997-05-02 | — | — | EP | disclosed |
| US-4561862-A | Use of selected beta-nitroalkenes as cetane number boosters for diesel fuel | OLIN CORPORATION (US) | 1985-12-31 | — | — | US | disclosed |
| US-4058541-A | Preparation of 2-alkanoyloxy-alkanoic | TEXACO INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-4058540-A | FROM A NITROALKYL NITRATE OR NITRO ALCOHOL AND ALKANOIC ACID, CALCIUM OCIDE OR CARBOXYLATE CATALYST | TEXACO INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-4040977-A | HALOACETAMIDE OR THIOCYANOACETAMIDE-ALCOHOL-FORMALDEHYDE CONDENSATES | STERLING DRUG INC. (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049241-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ADRB2, ADRB1, ADRA1B | ALDH1A1 463/4885NFKB1 3186/4885GPR84 190/4885 |
| US-20030187047-A1 | Conformationally rigid bicyclic and adamantane derivatives useful as alpha2-adrenergic blocking agents | ADRB2, ADRB1, ADRA1B | ALDH1A1 463/4885NFKB1 3186/4885GPR84 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.